Allegra Rollo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Allegra Rollo has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Aaron Seto
1 shared publication- Alexis Gadson
Shady Grove Fertility Center, Rockville, MD 20850, USA
1 shared publication Christopher Schmid
1 shared publication- Eli Y. Adashi
Brown University, Providence, Rhode Island, USA
1 shared publication Elizabeth S. Chen
1 shared publicationEmma Laquinta
1 shared publication
Latest Publications
- Open Access
- 29 September 2026
- Published by Cambridge University Press (CUP) in Journal of Law, Medicine & Ethics
- p. 1-3
The Henrietta Lacks Case: Ongoing Litigation Seeks Closure
The litigation brought by the Estate of Henrietta Lacks against Thermo Fisher Scientific, Ultragenyx Pharmaceutical, and Novartis Pharmaceuticals reframes benefit-sharing from voluntary institutional ethics into an enforceable legal duty. By pleading a single equitable claim — unjust enrichment — the Estate seeks to bypass the property and informed-consent doctrines that have defeated comparable tissue-appropriation suits, while accepting distinctive risks involving remoteness, limitations, causation, and apportionment. This commentary examines the strategy’s strengths and vulnerabilities through the still-pending Ultragenyx case, and considers its implications for research consent, prospective benefit-sharing frameworks, and bioethics pedagogy. Whether or not the remaining claim succeeds, the litigation has already altered the conversation about who should profit from human biological materials.
- 29 September 2026
- Published by Cambridge University Press (CUP) in Journal of Law, Medicine & Ethics
- p. 1-3
Open AccessThe Henrietta Lacks Case: Ongoing Litigation Seeks Closure
The litigation brought by the Estate of Henrietta Lacks against Thermo Fisher Scientific, Ultragenyx Pharmaceutical, and Novartis Pharmaceuticals reframes benefit-sharing from voluntary institutional ethics into an enforceable legal duty. By pleading a single equitable claim — unjust enrichment — the Estate seeks to bypass the property and informed-consent doctrines that have defeated comparable tissue-appropriation suits, while accepting distinctive risks involving remoteness, limitations, causation, and apportionment. This commentary examines the strategy’s strengths and vulnerabilities through the still-pending Ultragenyx case, and considers its implications for research consent, prospective benefit-sharing frameworks, and bioethics pedagogy. Whether or not the remaining claim succeeds, the litigation has already altered the conversation about who should profit from human biological materials.
- 21 October 2024
- Published by Elsevier in Fertility and Sterility
- Vol. 122 (4) , e97-e98
IMPACT OF THE FERTILITY PRESERVATION INSURANCE MANDATE ON FERTILITY PRESERVATION SERVICES AMONG REPRODUCTIVE-AGED FEMALE BREAST CANCER PATIENTS IN RHODE ISLAND
- 21 October 2024
- Published by Elsevier in Fertility and Sterility
- Vol. 122 (4) , e97-e98
IMPACT OF THE FERTILITY PRESERVATION INSURANCE MANDATE ON FERTILITY PRESERVATION SERVICES AMONG REPRODUCTIVE-AGED FEMALE BREAST CANCER PATIENTS IN RHODE ISLAND
- Open Access
- 14 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (4) , 1072
The Status of Fertility Preservation (FP) Insurance Mandates and Their Impact on Utilization and Access to Care
Fertility preservation (FP) is the use of a specific medical intervention to protect the fertility of individuals whose disease or disease treatment may lead to infertility. These medical interventions include the cryopreservation of oocytes, embryos, ovarian tissue, sperm, and testicular tissue; oocyte and embryo cryopreservation are the most widely used interventions in the United States. Although guidelines recommend FP prior to undergoing gonadotoxic treatments, cost barriers are high. For example, the average cost of an oocyte cryopreservation cycle in the United States exceeds $10,000. High cost and lack of insurance coverage are two of the most cited reasons explaining the low Reproductive Endocrinology and Infertility (REI) referral rates and limited FP utilization. Broadening insurance mandates for FP prior to gonadotoxic treatments could improve utilization and provide cancer survivors with improved quality of life post treatment.
- 14 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (4) , 1072
Open AccessThe Status of Fertility Preservation (FP) Insurance Mandates and Their Impact on Utilization and Access to Care
Fertility preservation (FP) is the use of a specific medical intervention to protect the fertility of individuals whose disease or disease treatment may lead to infertility. These medical interventions include the cryopreservation of oocytes, embryos, ovarian tissue, sperm, and testicular tissue; oocyte and embryo cryopreservation are the most widely used interventions in the United States. Although guidelines recommend FP prior to undergoing gonadotoxic treatments, cost barriers are high. For example, the average cost of an oocyte cryopreservation cycle in the United States exceeds $10,000. High cost and lack of insurance coverage are two of the most cited reasons explaining the low Reproductive Endocrinology and Infertility (REI) referral rates and limited FP utilization. Broadening insurance mandates for FP prior to gonadotoxic treatments could improve utilization and provide cancer survivors with improved quality of life post treatment.